BDH Industries Ltd
Incorporated in 1935, BDH Industries Ltd manufactures therapeutic formulations covering wide range of pharmaceuticals[1]
- Market Cap ₹ 213 Cr.
- Current Price ₹ 370
- High / Low ₹ 524 / 241
- Stock P/E 20.4
- Book Value ₹ 123
- Dividend Yield 1.20 %
- ROCE 17.8 %
- ROE 14.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 27.4%
Cons
- The company has delivered a poor sales growth of 2.26% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42 | 44 | 46 | 43 | 41 | 52 | 59 | 57 | 69 | 74 | 86 | 67 | 85 | |
| 39 | 40 | 42 | 38 | 36 | 45 | 51 | 49 | 60 | 64 | 73 | 55 | 72 | |
| Operating Profit | 4 | 4 | 4 | 5 | 5 | 7 | 9 | 9 | 9 | 11 | 12 | 12 | 13 |
| OPM % | 9% | 9% | 9% | 11% | 13% | 14% | 15% | 15% | 13% | 15% | 14% | 17% | 15% |
| 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | |
| Interest | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 3 | 4 | 5 | 5 | 5 | 7 | 8 | 9 | 10 | 11 | 13 | 12 | 14 |
| Tax % | 33% | 32% | 33% | 33% | 27% | 26% | 27% | 27% | 24% | 26% | 25% | 26% | |
| 2 | 3 | 3 | 3 | 4 | 5 | 6 | 6 | 7 | 8 | 10 | 9 | 10 | |
| EPS in Rs | 3.99 | 4.46 | 5.61 | 5.80 | 6.53 | 8.39 | 10.32 | 11.05 | 12.54 | 14.24 | 17.14 | 16.10 | 18.11 |
| Dividend Payout % | 31% | 39% | 37% | 36% | 36% | 34% | 25% | 28% | 29% | 28% | 26% | 28% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 2% |
| 3 Years: | -1% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 9% |
| 3 Years: | 10% |
| TTM: | 7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 33% |
| 3 Years: | 46% |
| 1 Year: | 37% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 15% |
| 3 Years: | 16% |
| Last Year: | 14% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 17 | 18 | 21 | 23 | 25 | 28 | 32 | 37 | 43 | 49 | 56 | 63 | 65 |
| 11 | 9 | 9 | 8 | 8 | 13 | 9 | 9 | 2 | 5 | 9 | 1 | 0 | |
| 14 | 19 | 15 | 17 | 18 | 18 | 18 | 19 | 18 | 20 | 23 | 17 | 18 | |
| Total Liabilities | 48 | 52 | 52 | 54 | 57 | 66 | 65 | 71 | 69 | 80 | 93 | 87 | 89 |
| 15 | 13 | 13 | 23 | 23 | 22 | 21 | 20 | 20 | 19 | 20 | 20 | 19 | |
| CWIP | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 33 | 38 | 35 | 31 | 34 | 44 | 44 | 51 | 49 | 61 | 73 | 67 | 69 | |
| Total Assets | 48 | 52 | 52 | 54 | 57 | 66 | 65 | 71 | 69 | 80 | 93 | 87 | 89 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 | 6 | 4 | 7 | -0 | -4 | 11 | 1 | 3 | 6 | -2 | 15 | |
| -0 | -0 | -5 | -5 | 0 | 1 | 1 | 1 | 1 | 0 | -0 | 2 | |
| 3 | -3 | -1 | -3 | -3 | 3 | -6 | -2 | -8 | 0 | 1 | -10 | |
| Net Cash Flow | 6 | 3 | -1 | -1 | -2 | 0 | 6 | -0 | -4 | 7 | -1 | 6 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 81 | 64 | 67 | 63 | 89 | 68 | 96 | 76 | 82 | 121 | 78 |
| Inventory Days | 65 | 71 | 61 | 39 | 95 | 89 | 51 | 53 | 50 | 53 | 30 | 65 |
| Days Payable | 144 | 201 | 162 | 192 | 244 | 188 | 158 | 171 | 123 | 139 | 128 | 134 |
| Cash Conversion Cycle | -11 | -49 | -37 | -85 | -85 | -10 | -39 | -21 | 4 | -5 | 23 | 9 |
| Working Capital Days | -74 | -76 | -72 | -90 | -60 | -29 | -31 | 6 | 56 | 49 | 71 | 102 |
| ROCE % | 13% | 13% | 15% | 14% | 14% | 16% | 19% | 18% | 18% | 20% | 21% | 18% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Domestic Revenue ₹ In Lakhs |
|
|||||||||||
| Export Revenue ₹ In Lakhs |
||||||||||||
| Number of Employees Number |
||||||||||||
| Installed Wind Power Capacity MW |
||||||||||||
| Electrical Energy Generated (Wind) kWh |
||||||||||||
| Gross Current Asset (GCA) Days Days |
||||||||||||
| R&D Expenditure (Percentage of Turnover) % |
||||||||||||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
26 Feb - Notice of special window opened for a period of one year from 5th February 2026 to 4th February 2027 to facilitate transfer and dematerialisation of …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Feb - Standalone Unaudited Financial Results of the Company for the third quarter and nine months ended on 31st December 2025 of the financial year 2025-26 published …
-
Standalone Unaudited Financial Results For The Third Quarter And Nine Months Ended On 31St December 2025 Of The Financial Year 2025-26.
11 Feb - Board approved standalone unaudited Q3 and 9M results for period ended 31 Dec 2025; limited review dated 11 Feb 2026.
-
Board Meeting Outcome for OUTCOME OF BOARD MEETING
11 Feb - Approved standalone unaudited Q3 and nine-month results ended 31-Dec-2025; limited review dated 11-Feb-2026.
-
Board Meeting Intimation for Considering And Approving The Standalone Unaudited Financial Results For The Third Quarter And Nine Months Ended On 31St December 2025 Of The Financial Year 2025-26.
3 Feb - Board meeting 11 Feb 2026 to consider standalone Q3/nine-month results (31 Dec 2025); trading window closed Jan1–Feb13,2026
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
BDHIL is a full-service Contract Manufacturing Organization for production of Pharmaceutical, Oncological Products and associated packaging services. It is an exporter and manufacturer of therapeutic formulations covering a wide range of pharmaceuticals